Researchers from the Johns Hopkins University in the US have invented a class of immunotherapy drugs, Y-traps, designed to use the body’s immune system to fight cancer.
Y-traps are Y-shaped molecules that are fused to a molecular ‘trap’ to capture nearby molecules and make them ineffective.
A major way tumors evade the immune system is via regulatory T cells (Tregs) that turn off the immune system’s ability to attack tumor cells. Tumors are frequently infiltrated by Tregs, and this is strongly correlated with poor outcome in multiple cancer types.
Initially, the new Y-trap drugs were formulated to disable cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and transforming growth factor-beta (TGFbeta), proteins that promote the development of Tregs. This allows anti-tumor immune cells to fight the tumor and turns down Treg cells.
Preclinical data from the university’s study demonstrated a significant reduction in tumour growth when Y-traps were used, including cancers that do not respond to current immunotherapies.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAssociate professor of otolaryngology at the Johns Hopkins University Atul Bedi said: “Tregs have long been a thorn in the side of cancer immunotherapy. We’ve finally found a way to overcome this hurdle with this CTLA-4-targeted Y-trap.”
Another Y-trap developed to target PD-L1 and trap TGFbeta demonstrated better efficacy than existing PD-L1-targeting drugs atezolizumab and avelumab. It also decreased the tumour growth of cancers that had not previously responded to drugs.
Bedi added: “We have already invented a whole family of these multifunctional molecules based on the Y-trap technology.
“Since mechanisms of immune dysfunction are shared across many types of cancer, this approach could have broad impact for improving cancer immunotherapy.”
As well as treating patients with advanced metastatic cancers, Bedi expects to potentially use the new class of drugs as a neoadjuvant therapy prior to surgery to create a ‘vaccine’ effect and preventing disease recurrence.
